PLX Stock Forecast: Protalix Biotherapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Protalix Biotherapeutics, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 94 of 100 as at 21 Nov 2026 — among the strongest tenth.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Protalix Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PLX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PLX.
This page is one stock. Monday covers all of them.
PLX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PLX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Protalix Biotherapeutics, Inc. returned +66.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PLX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 12.3×
- Price / sales
- 2.9×
- Price / book
- 3.0×
- EV / EBITDA
- 8.2×
Cheaper than 64% of US stocks
Cheaper than 37% of US stocks
Cheaper than 30% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- 22.8%
- Earnings growth (YoY)
- 68.2%
- Gross margin
- 61.0%
- Operating margin
- 29.8%
- Net margin
- 24.3%
Higher than 72% of US stocks
Higher than 79% of US stocks
Higher than 74% of US stocks
Higher than 87% of US stocks
Higher than 84% of US stocks
- Return on equity
- 30.8%
- Return on assets
- 15.7%
- Dividend yield
- —
Higher than 88% of US stocks
Higher than 97% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Protalix Biotherapeutics, Inc. has a market value of $258.0M and an enterprise value of $218.6M.
Revenue in the twelve months to 30 June 2026: $80.6M. The latest quarter grew 27.1% year on year.
Net income over the same four quarters: $18.9M, a 23.5% net margin.
Free cash flow in the twelve months to 30 June 2026: $7.7M.
Trailing P/E: 12.3×; forward P/E: 4.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Protalix Biotherapeutics, Inc. employs 226 people — $357K of revenue per employee.
Data provided by Twelve Data
PLX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PLX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Protalix Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PLX
What is the PLX stock price forecast for 2026-2027?
The median 12-month analyst price target for Protalix Biotherapeutics, Inc. is $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PLX stock a buy right now?
Of the 2 analysts covering Protalix Biotherapeutics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protalix Biotherapeutics, Inc. 94 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PLX?
As at 21 Nov 2026, Protalix Biotherapeutics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
Will PLX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $12, and Ticker Nerd's factor model ranks Protalix Biotherapeutics, Inc. 94 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PLX stock forecast for 2030?
No analyst covering Protalix Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
How has PLX stock performed over the past year?
Protalix Biotherapeutics, Inc. returned +66.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Protalix Biotherapeutics, Inc. do?
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company’s current portfolio centers on treatments for rare diseases, including Elelyso for Gaucher disease and Elfabrio for adult patients with Fabry disease.
About Protalix Biotherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company’s current portfolio centers on treatments for rare diseases, including Elelyso for Gaucher disease and Elfabrio for adult patients with Fabry disease. Protalix also advances a pipeline of plant cell-expressed candidates such as PRX-115 for gout and PRX-119 for NETs-related diseases, reflecting its emphasis on enzyme replacement therapies and other biologic approaches for conditions with limited treatment options. Based in Karmiel, Israel, Protalix serves global markets through product commercialization and partnership-based development across its specialty biopharmaceutical programs.
CEO Mr. Dror Bashan · 226 employees · United States · https://www.protalix.com